Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ambagon Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://ambagontx.com/
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jul 10, 2024
Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Nov 15, 2022
Finance
MRL Ventures targets company creation, new modalities
Corporate VC has increasing focus on next-generation technologies that are outside Merck’s R&D priorities
BioCentury | Nov 11, 2022
Product Development
Molecular glue degraders: moving beyond IMiDs
Technologies unraveling the relationships between glue structures and conformational changes are opening up new targets and E3 ligases
BioCentury | Jun 7, 2022
Data Byte
Top series A rounds of U.S. biotechs year to date
The year has seen 11 U.S. therapeutics developers raise series As of $75M or more, mostly funding new modality platform plays
BioCentury | Feb 2, 2022
Emerging Company Profile
Ambagon: creating molecular glues for disordered proteins
Nextech Invest leads $85M series A to make the difficult-to-drug protein class amenable to small molecules
BioCentury | Jan 7, 2022
Deals
Jan. 6 Quick Takes: Nextech leads $85M A round for molecular glue newco Ambagon
Plus: Odyssey builds out tool kit and updates from Amgen-Generate, Verily-Sosei, TRexBio-Janssen, Sutro, Sanofi and more
Items per page:
1 - 9 of 9